Business Context and Reporting Period
This Form 8-K filing by Protagonist Therapeutics, Inc. (a Delaware corporation and emerging growth company) reports a corporate governance event dated June 7, 2017. The filing details the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance.
Material Changes
- Board Composition: The Board increased the number of authorized directors from six to seven.
- Director Appointment: Lewis T. "Rusty" Williams, M.D., Ph.D., was appointed as a Class II director effective June 7, 2017, serving until the 2018 Annual Meeting of Stockholders.
- Independence: The Board determined Dr. Williams is an independent director under Nasdaq listing standards.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Cash: Annual cash compensation of $40,000, paid in quarterly installments prorated for partial service.
- Initial Equity Grant: An option to purchase 24,000 shares of common stock, granted on June 15, 2017, at the closing price on the grant date. Vesting occurs in 36 equal monthly installments contingent on continuous service.
- Future Equity Grants: Eligibility for annual option grants of 12,000 shares on the date of each annual meeting, vesting at the earlier of one year or the next annual meeting.
- Committee Service: Additional cash compensation is available if appointed to a Board committee; no committee assignments were determined at the time of filing.
Risks and Contingencies: The filing states there were no arrangements or understandings regarding the selection of Dr. Williams and no related person transactions requiring disclosure. An indemnification agreement consistent with those of other directors will be executed.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 24,000-share option grant to Dr. Williams.
- Confirm the total number of authorized directors is now seven.
- Monitor future filings for Dr. Williams' specific committee assignments and any associated additional compensation.
- Review the Company's Non-Employee Director Compensation Policy for details on future annual grants.